PortfoliosLab logoPortfoliosLab logo
ANIP vs. OCUL
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ANIP vs. OCUL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ANI Pharmaceuticals, Inc. (ANIP) and Ocular Therapeutix, Inc. (OCUL). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ANIP achieves a 2.08% return, which is significantly higher than OCUL's -17.87% return. Over the past 10 years, ANIP has underperformed OCUL with an annualized return of 4.02%, while OCUL has yielded a comparatively higher 6.79% annualized return.


ANIP

1D
1.37%
1M
-2.59%
YTD
2.08%
6M
-0.17%
1Y
22.91%
3Y*
15.92%
5Y*
19.64%
10Y*
4.02%

OCUL

1D
5.73%
1M
21.14%
YTD
-17.87%
6M
-23.07%
1Y
22.63%
3Y*
26.98%
5Y*
-7.10%
10Y*
6.79%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ANIP vs. OCUL - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ANIP
ANI Pharmaceuticals, Inc.
2.08%42.80%0.25%37.06%-12.70%58.68%-52.91%36.98%-30.15%6.32%
OCUL
Ocular Therapeutix, Inc.
-17.87%42.15%91.48%58.72%-59.68%-66.33%424.05%-0.75%-10.56%-46.83%

Correlation

The correlation between ANIP and OCUL is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.20

Correlation (3Y)
Calculated over the trailing 3-year period

0.30

Correlation (5Y)
Calculated over the trailing 5-year period

0.33

Correlation (10Y)
Calculated over the trailing 10-year period

0.31

Correlation (All Time)
Calculated using the full available price history since Jul 25, 2014

0.31

The correlation between ANIP and OCUL shifts across timeframes, from 0.20 (1 year) to 0.33 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

ANIP:

$1.74B

OCUL:

$2.23B

EPS

ANIP:

$4.26

OCUL:

-$1.45

PS Ratio

ANIP:

1.84

OCUL:

38.49

PB Ratio

ANIP:

3.09

OCUL:

3.84

Total Revenue (TTM)

ANIP:

$923.71M

OCUL:

$52.04M

Gross Profit (TTM)

ANIP:

$486.11M

OCUL:

$45.40M

EBITDA (TTM)

ANIP:

$234.71M

OCUL:

-$283.03M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ANIP vs. OCUL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ANIP
ANIP Risk / Return Rank: 6060
Overall Rank
ANIP Sharpe Ratio Rank: 6363
Sharpe Ratio Rank
ANIP Sortino Ratio Rank: 6363
Sortino Ratio Rank
ANIP Omega Ratio Rank: 5959
Omega Ratio Rank
ANIP Calmar Ratio Rank: 6060
Calmar Ratio Rank
ANIP Martin Ratio Rank: 5858
Martin Ratio Rank

OCUL
OCUL Risk / Return Rank: 5353
Overall Rank
OCUL Sharpe Ratio Rank: 5353
Sharpe Ratio Rank
OCUL Sortino Ratio Rank: 5757
Sortino Ratio Rank
OCUL Omega Ratio Rank: 5555
Omega Ratio Rank
OCUL Calmar Ratio Rank: 5252
Calmar Ratio Rank
OCUL Martin Ratio Rank: 5050
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ANIP vs. OCUL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ANI Pharmaceuticals, Inc. (ANIP) and Ocular Therapeutix, Inc. (OCUL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ANIPOCULDifference
Sharpe ratioReturn per unit of total volatility

+0.32

Sortino ratioReturn per unit of downside risk

+0.28

Omega ratioGain probability vs. loss probability

1.15

1.13

+0.02

Calmar ratioReturn relative to maximum drawdown

0.80

0.40

+0.41

Martin ratioReturn relative to average drawdown

1.48

0.75

+0.73

ANIP vs. OCUL - Sharpe Ratio Comparison

The current ANIP Sharpe Ratio is 0.65, which is higher than the OCUL Sharpe Ratio of 0.32. The chart below compares the historical Sharpe Ratios of ANIP and OCUL, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ANIP vs. OCUL - Drawdown Comparison

The maximum ANIP drawdown since its inception was -98.81%, roughly equal to the maximum OCUL drawdown of -95.19%. Use the drawdown chart below to compare losses from any high point for ANIP and OCUL.


Loading charts...

Drawdown Indicators


ANIPOCULDifference

Max Drawdown

Largest peak-to-trough decline

-98.81%

-95.19%

-3.62%

Max Drawdown (1Y)

Largest decline over 1 year

-28.66%

-57.29%

+28.63%

Max Drawdown (3Y)

Largest decline over 3 years

-28.66%

-61.57%

+32.91%

Max Drawdown (5Y)

Largest decline over 5 years

-59.38%

-85.78%

+26.40%

Max Drawdown (10Y)

Largest decline over 10 years

-72.96%

-90.94%

+17.98%

Current Drawdown

Current decline from peak

-82.09%

-76.96%

-5.13%

Average Drawdown

Average peak-to-trough decline

-79.39%

-76.60%

-2.79%

Ulcer Index

Depth and duration of drawdowns from previous peaks

15.54%

30.45%

-14.91%

Volatility

ANIP vs. OCUL - Volatility Comparison

The current volatility for ANI Pharmaceuticals, Inc. (ANIP) is 9.06%, while Ocular Therapeutix, Inc. (OCUL) has a volatility of 17.46%. This indicates that ANIP experiences smaller price fluctuations and is considered to be less risky than OCUL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ANIPOCULDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.06%

17.46%

-8.40%

Volatility (6M)

Calculated over the trailing 6-month period

24.48%

54.60%

-30.12%

Volatility (1Y)

Calculated over the trailing 1-year period

35.60%

70.19%

-34.59%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

46.33%

78.55%

-32.22%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

48.20%

78.85%

-30.65%

Dividends

ANIP vs. OCUL - Dividend Comparison

Neither ANIP nor OCUL has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ANIP vs. OCUL - Financials Comparison

This section allows you to compare key financial metrics between ANI Pharmaceuticals, Inc. and Ocular Therapeutix, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M250.00M20222023202420252026
237.46M
10.79M
(ANIP) Total Revenue
(OCUL) Total Revenue
Values in USD except per share items

Frequently Asked Questions


ANIP and OCUL have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

OCUL has higher volatility (17.46%) compared to ANIP (9.06%). In terms of maximum drawdown, ANIP dropped -98.81% vs OCUL's -95.19%.

ANIP currently has the higher Sharpe Ratio (0.65 vs 0.32), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ANIP and OCUL

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer